Fractyl raises $55 million in series e financing to advance revita dmr for type 2 diabetes

Fractyl's first close of $55 million will be used to support the revita t2di pivotal us clinical trial of revita dmr to treat type 2 diabetes.
MDGL Ratings Summary
MDGL Quant Ranking